Who are Zaroxolyn's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lozol, Catechin, Combipres, CHLORTHALIDONE, Metolazone concurrently with furosemide, Indapamide (T2).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metolazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Zaroxolyn — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zaroxolyn (METOLAZONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazide-like Diuretic [EPC]. Area: Cardiovascular.

marketed Thiazide-like Diuretic [EPC] Carbonic anhydrase 7 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Zaroxolyn (METOLAZONE) — I3 Pharms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zaroxolyn TARGET	METOLAZONE	I3 Pharms	marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1973-01-01
Lozol	INDAPAMIDE		marketed	Thiazide-like Diuretic [EPC]	Carbonic anhydrase 7	1983-01-01
Catechin	CIANIDANOL		marketed		Carbonic anhydrase 7	1977-01-01
Combipres	Chlortalidone	University Hospital Birmingham	marketed	Thiazide-like Diuretic	Carbonic anhydrase 7	1960-01-01
CHLORTHALIDONE	CHLORTHALIDONE		marketed	Thiazide-like Diuretic [EPC]	Na+/Cl− cotransporter	1960-01-01
Metolazone concurrently with furosemide	Metolazone concurrently with furosemide	University of Maryland, Baltimore	marketed	Thiazide-like diuretic and loop diuretic combination	Sodium-chloride cotransporter (NCC) and sodium-potassium-chloride cotransporter (NKCC2)
Indapamide (T2)	Indapamide (T2)	Hospices Civils de Lyon	marketed	Thiazide-like diuretic	Sodium-chloride cotransporter (NCC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Combipres · 9066936 · US
2030-02-04 — Combipres · 9169238 · US
2031-07-01 — Combipres · 9387249 · US

Sponsor landscape (Thiazide-like Diuretic [EPC] class)

· 2 drugs in this class
I3 Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zaroxolyn — Competitive Intelligence Brief. https://druglandscape.com/ci/metolazone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab